Challenges in the gynecologic care of premenopausal women with breast cancer

Mayo Clinic Proceedings

Volumn 86, Issue 3, 2011, Pages 229-240

  Bakkum Gamez, Jamie N ^a   Laughlin, Shannon K ^a   Jensen, Jani R ^a   Akogyeram, Clement O ^a   Pruthi, Sandhya ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; CARRIER PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRADIOL; FLUOROURACIL; FLUOXETINE; GABAPENTIN; IBUPROFEN; MEFENAMIC ACID; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; PACLITAXEL; PAROXETINE; PLACEBO; PREMARIN CONJUGATED ESTROGEN CREAM; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEX HORMONE; TAMOXIFEN; TRANEXAMIC ACID; TRASTUZUMAB; UNCLASSIFIED DRUG; VENLAFAXINE;

ABDOMINAL PAIN; ANOVULATION; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CAUSAL ATTRIBUTION; CONTRACEPTION; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG CONTRAINDICATION; ENDOMETRIUM ABLATION; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FERTILITY; GYNECOLOGIC CARE; HORMONE RESPONSE; HOT FLUSH; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; LIBIDO DISORDER; MENORRHAGIA; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY INSUFFICIENCY; PREGNANCY OUTCOME; PREMENOPAUSE; PROGESTERONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; REVIEW; SEXUAL DYSFUNCTION; STOMACH HEMORRHAGE; TREATMENT INDICATION; TREATMENT RESPONSE; ULCER; UTERUS BLEEDING; VAGINAL DRYNESS; VASOMOTOR DISORDER;

EID: 79952396229     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0794     Document Type: Review

References (133)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. National Cancer Institute. Surveillance Epidemiology and End Results Web site. SEER stat fact sheets: breast. http://seer.cancer.gov/statfacts/html/ breast.html. Accessed January 19, 2011.
4. Bonnier P, Romain S, Dilhuydy JM, et al; Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Influence of pregnancy on the outcome of breast cancer: a case-control study. Int J Cancer. 1997;72:720-727. (Pubitemid 27431510)
5. Partridge AH, Gelber S, Peppercorn J, et al. Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer. 2008;8:65-69. (Pubitemid 351346231)
6. El-Hemaidi I, Gharaibeh A, Shehata H. Menorrhagia and bleeding disorders. Curr Opin Obstet Gynecol. 2007;19:513-520. (Pubitemid 350135433)
7. Stewart EA. Uterine fibroids. Lancet. 2001;357:293-298. (Pubitemid 32120866)
8. Kucera E, Holub Z, Svobodova G. Laparoscopic oophorectomy either with or without hysterectomy for early breast cancer. Eur J Gynaecol Oncol. 2007;28:294-296. (Pubitemid 47237998)
9. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53:58-68. (Pubitemid 13245381)
10. Maruyama Y, Aoki N, Suzuki Y, et al. Sex-steroid-binding plasma protein (SBP), testosterone, oestradiol and dehydroepiandrosterone (DHEA) in prepuberty and puberty. Acta Endocrinol (Copenh). 1987;114:60-67. (Pubitemid 17216985)
11. Selby C. Sex hormone binding globulin: origin, function and clinical significance. Ann Clin Biochem. 1990;27(pt 6):532-541. (Pubitemid 20377170)
12. Bernardes JR Jr, Nonogaki S, Seixas MT, Rodrigues de Lima G, Baracat EC, Gebrim LH. Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynaecol Obstet. 1999;67:33-38. (Pubitemid 29495979)
13. Faupel-Badger JM, Prindiville SA, Venzon D, Vonderhaar BK, Zujewski JA, Eng-Wong J. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:1153-1158.
14. American College of Obstetricians and Gynecologists. ACOG practice bulletin: alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008;112(2, pt 1):387-400.
15. Hesley GK, Gorny KR, Henrichsen TL, Woodrum DA, Brown DL. A clinical review of focused ultrasound ablation with magnetic resonance guidance: an option for treating uterine fibroids. Ultrasound Q. 2008;24:131-139.
16. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989;160:126-131. (Pubitemid 19055273)
17. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90:434-440. (Pubitemid 27357938)
18. Varma R, Soneja H, Bhatia K, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia: a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139:169-175.
19. Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol. 2003;188:1297-1298. (Pubitemid 36589125)
20. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-3253. (Pubitemid 37430077)
21. Hanstede MM, Tempany CM, Stewart EA. Focused ultrasound surgery of intramural leiomyomas may facilitate fertility: a case report. Fertil Steril. 2007;88(2):497.e5-497.e7.
22. Rabinovici J, David M, Fukunishi H, Morita Y, Gostout BS, Stewart EA. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril. 2010;93:199-209.
23. Rabinovici J, Inbar Y, Eylon SC, Schiff E, Hananel A, Freundlich D. Pregnancy and live birth after focused ultrasound surgery for symptomatic focal adenomyosis: a case report. Hum Reprod. 2006;21:1255-1259.
24. Homer H, Saridogan E. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril. 2010;94:324-330.
25. Walker WJ, McDowell SJ. Pregnancy after uterine artery embolization for leiomyomata: a series of 56 completed pregnancies. Am J Obstet Gynecol. 2006;195:1266-1271. (Pubitemid 44635371)
26. Feng C, Sun CC, Wang TT, He RH, Sheng JZ, Huang HF. Decreased expression of endometrial vessel AQP1 and endometrial epithelium AQP2 related to anovulatory uterine bleeding in premenopausal women. Menopause. 2008;15:648-654.
27. Hickey M, Higham J, Fraser IS. Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev. 2007;CD001895.
28. Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100:475-482.
29. Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. Drug Saf. 2004;27:75-90. (Pubitemid 38186951)
30. Nelson AL, Teal SB. Medical therapies for chronic menorrhagia. Obstet Gynecol Surv. 2007;62:272-281. (Pubitemid 46555922)
31. Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;CD000400.
32. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;(4):CD000249.
33. Rybo G. Tranexamic acid therapy effective treatment in heavy menstrual bleeding: clinical update. Thera Adv. 1991;4:1-8.
34. Oertli D, Laffer U, Haberthuer F, Kreuter U, Harder F. Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer. Br J Surg. 1994;81:856-859. (Pubitemid 24204809)
35. El-Nashar SA, Hopkins MR, Creedon DJ, Cliby WA, Famuyide AO. Efficacy of bipolar radiofrequency endometrial ablation vs thermal balloon ablation for management of menorrhagia: a population-based cohort. J Minim Invasive Gynecol. 2009;16:692-699.
36. El-Nashar SA, Hopkins MR, Creedon DJ, et al. Prediction of treatment outcomes after global endometrial ablation. Obstet Gynecol. 2009;113:97-106.
37. Krogh RA, Lauszus FF, Guttorm E, Rasmussen K. Surgery and cancer after endometrial resection: long-term follow-up on menstrual bleeding and hormone treatment by questionnaire and registry. Arch Gynecol Obstet. 2009;280:911-916.
38. Valle RF, Baggish MS. Endometrial carcinoma after endometrial ablation: high-risk factors predicting its occurrence. Am J Obstet Gynecol. 1998;179:569-572. (Pubitemid 28447227)
39. McCausland AM, McCausland VM. Long-term complications of endometrial ablation: cause, diagnosis, treatment, and prevention. J Minim Invasive Gynecol. 2007;14:399-406. (Pubitemid 47042624)
40. Ahonkallio SJ, Liakka AK, Martikainen HK, Santala MJ. Feasibility of endometrial assessment after thermal ablation. Eur J Obstet Gynecol Reprod Biol. 2009;147:69-71.
41. Mirena (levonorgestrel-releasing intrauterine system) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2009.
42. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf). 1982;17:529-536. (Pubitemid 12006959)
43. Xiao B, Zeng T, Wu S, Sun H, Xiao N. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after longterm use. Contraception. 1995;51:359-365.
44. Kuhnz W, Fritzemeier KH, Hegele-Hartung C, Krattenmacher R. Comparative progestational activity of norgestimate, levonorgestrel-oxime and levonorgestrel in the rat and binding of these compounds to the progesterone receptor. Contraception. 1995;51:131-139.
45. Trinh XB, van Dam PA, Tjalma WA. Plasma concentrations of levonorgestrel in patients with an intrauterine progestogen delivery system: do they have any significance? Maturitas. 2006;55:94-95.
46. Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrelreleasing intrauterine system and breast cancer. Obstet Gynecol. 2005;106:813-817. (Pubitemid 41362188)
47. Concin H, Bosch H, Hintermuller P, et al. Use of the levonorgestrelreleasing intrauterine system: an Austrian perspective. Curr Opin Obstet Gynecol. 2009;21(suppl 1):S1-S9.
48. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril. 2008;90:17-22. (Pubitemid 351885178)
49. Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer. 2010;126:483-489.
50. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
51. Osborne CK, Elledge RM, Fuqua SAW. Estrogen receptors in breast cancer therapy. Sci Am Sci Med. 1996;3:32-41.
52. Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev. 1999;20:253-278.
53. Zarbo G, Caruso G, Zammitti M, Caruso S, Zarbo R. The effects of tamoxifen therapy on the endometrium. Eur J Gynaecol Oncol. 2000;21:86-88. (Pubitemid 30088098)
54. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527-537. (Pubitemid 24111008)
55. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol. 2006;107:1475-1478.
56. Neumannova M, Kauppila A, Kivinen S, Vihko R. Short-term effects of tamoxifen, medroxyprogesterone acetate, and their combination on receptor kinetics and 17 beta-hydroxysteroid dehydrogenase in human endometrium. Obstet Gynecol. 1985;66:695-700. (Pubitemid 16216162)
57. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 1991;9:1283-1297.
58. Buijs C, Willemse PH, de Vries EG, et al. Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patients. Int J Gynecol Cancer. 2009;19:677-681.
59. McGonigle KF, Lantry SA, Odom-Maryon TL, Chai A, Vasilev SA, Simpson JF. Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. Cancer Lett. 1996;101:59-66. (Pubitemid 26060193)
60. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997;66:233-237.
61. Taponeco F, Curcio C, Fasciani A, et al. Indication of hysteroscopy in tamoxifen treated breast cancer patients. J Exp Clin Cancer Res. 2002;21:37-43. (Pubitemid 34309230)
62. Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat. 1998;48:81-85. (Pubitemid 28073536)
63. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89:1765-1772.
64. Ozdemir S, Celik C, Gezginc K, Kiresi D, Esen H. Evaluation of endometrial thickness with transvaginal ultrasonography and histopathology in premenopausal women with abnormal vaginal bleeding. Arch Gynecol Obstet. 2010;282:395-399.
65. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2009;CD007245.
66. Chan SS, Tam WH, Yeo W, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG. 2007;114:1510-1515. (Pubitemid 350077441)
67. Gardner FJ, Konje JC, Bell SC, et al. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol Oncol. 2009;114:452-456.
68. Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: a Nordic multicenter study. Am J Obstet Gynecol. 1995;172:1488-1494.
69. Mourits MJ, Van der Zee AG, Willemse PH, Ten Hoor KA, Hollema H, De Vries EG. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol. 1999;73:21-26. (Pubitemid 29177594)
70. Barthelmes L, Gateley CA. Tamoxifen and pregnancy. Breast. 2004;13:446-451. (Pubitemid 39618815)
71. Goldhirsch A, Gelber RD, Castiglione M; International Breast Cancer Study Group. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol. 1990;1:183-188.
72. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hematooncological neoplasias and other cancers. Leuk Lymphoma. 1999;33:65-76. (Pubitemid 29116395)
73. Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart FH, Kowal D, eds. Contraceptive Technology. New York, NY: Ardent Media; 2007.
74. Smith RD. Contemporary hysteroscopic methods for female sterilization. Int J Gynaecol Obstet. 2010;108:79-84.
75. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol. 1996;174:1161-1168.
76. Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception. 2008;77:10-21.
77. Lyus R, Lohr P, Prager S. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception. 2010;81:367-371.
78. Brockmeyer A, Kishen M, Webb A. Experience of IUD/IUS insertions and clinical performance in nulliparous women: a pilot study. Eur J Contracept Reprod Health Care. 2008;13:248-254.
79. Intrauterine devices: an effective alternative to oral hormonal contraception. Prescrire Int. 2009;18:125-130.
80. Essure [product information]. Mountain View, CA: Conceptus Inc; 2002-2009.
81. Adiana [product information]. Marlborough, MA: Hologic, Inc; 2009.
82. Berger GS, Keith L. Culdotomy for female sterilization. Int Surg. 1977;62:72-75. (Pubitemid 8072822)
83. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-975.
84. Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer: a pilot survey of survivors' attitudes and experiences. Cancer. 1999;86:697-709. (Pubitemid 29379417)
85. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917-2931. (Pubitemid 46655598)
86. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116:791-798.
87. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicincyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483-1496. (Pubitemid 20301179)
88. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718-1729. (Pubitemid 26134232)
89. Zambetti M, Bonadonna G, Valagussa P, et al. Adjuvant CMF for nodenegative and estrogen receptor-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992;(11):77-83.
90. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23:4347-4353. (Pubitemid 46207008)
91. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26:2630-2635.
92. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91:694-697.
93. Ernst E, Bergholdt S, Jorgensen JS, Andersen CY. The first woman to give birth to two children following transplantation of frozen/thawed ovarian tissue. Hum Reprod. 2010;25:1280-1281.
94. Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F, Nandi S. Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis. Proc Natl Acad Sci U S A. 2001;98:11755-11759. (Pubitemid 32928801)
95. Clarke RB. Ovarian steroids and the human breast: regulation of stem cells and cell proliferation. Maturitas. 2006;54:327-334.
96. Wohlfahrt J, Andersen PK, Mouridsen HT, Melbye M. Risk of latestage breast cancer after a childbirth. Am J Epidemiol. 2001;153:1079-1084. (Pubitemid 32493256)
97. Albrektsen G, Heuch I, Kvale G. The short-term and long-term effect of a pregnancy on breast cancer risk: a prospective study of 802,457 parous Norwegian women. Br J Cancer. 1995;72:480-484.
98. Kranick JA, Schaefer C, Rowell S, et al. Is pregnancy after breast cancer safe? Breast J. 2010;16:404-411.
99. de Bree E, Makrigiannakis A, Askoxylakis J, Melissas J, Tsiftsis DD. Pregnancy after breast cancer: a comprehensive review. J Surg Oncol. 2010;101:534-542.
100. Rippy EE, Karat IF, Kissin MW. Pregnancy after breast cancer: the importance of active counselling and planning. Breast. 2009;18:345-350.
101. Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004;100:465-469. (Pubitemid 38124762)
102. Kroman N, Jensen MB, Wohlfahrt J, Ejlertsen B. Pregnancy after treatment of breast cancer: a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol. 2008;47:545-549. (Pubitemid 351878435)
103. Averette HE, Mirhashemi R, Moffat FL. Pregnancy after breast carcinoma: the ultimate medical challenge. Cancer. 1999;85:2301-2304. (Pubitemid 29244835)
104. Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer. 1999;85:2424-2432. (Pubitemid 29244851)
105. Alder J, Zanetti R, Wight E, Urech C, Fink N, Bitzer J. Sexual dysfunction after premenopausal stage I and II breast cancer: do androgens play a role? J Sex Med. 2008;5:1898-1906.
106. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol. 2006;24:2815-2821. (Pubitemid 46655597)
107. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005;105:944-952. (Pubitemid 40571010)
108. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005;90:5226-5233. (Pubitemid 41262278)
109. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343:682-688.
110. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med. 2005;165:1582-1589. (Pubitemid 41124151)
111. Davis SR, van der Mooren MJ, van Lunsen RH, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause. 2006;13:387-396.
112. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001;97:855-866. (Pubitemid 32406196)
113. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med. 2005;2(suppl 3):154-165. (Pubitemid 41727408)
114. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259-263. (Pubitemid 26000605)
115. Ganz PA. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. Am J Med. 2005;118(suppl 12B):136-141.
116. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause. 2009;16:30-36.
117. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003;6:45-52. (Pubitemid 36398872)
118. Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer. 2005;41:2673-2681. (Pubitemid 41607558)
119. Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol. 2008;19:1669-1680.
120. Files JA, Ko MG, Pruthi S. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. Mayo Clin Proc. 2010;85(6):560-566.
121. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol. 2008;112:1053-1060.
122. Gabrielsson J, Wallenbeck I, Larsson G, Birgerson L, Heimer G. New kinetic data on estradiol in light of the vaginal ring concept. Maturitas. 1995;22(suppl):S35-S39. (Pubitemid 26021028)
123. Stearns V. Management of hot flashes in breast cancer survivors and men with prostate cancer. Curr Oncol Rep. 2004;6:285-290. (Pubitemid 39359498)
124. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137:805-813. (Pubitemid 35334452)
125. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol. 2006;24:2836-2841. (Pubitemid 46630583)
126. Tempfer CB, Froese G, Heinze G, Bentz EK, Hefler LA, Huber JC. Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med. 2009;122:939-946.e9.
127. Shu XO, Zheng Y, Cai H, et al. Soy food intake and breast cancer survival. JAMA. 2009;302:2437-2443.
128. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001;61:5045-5050. (Pubitemid 32681533)
129. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356:2059-2063. (Pubitemid 32009821)
130. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009;27:2831-2837.
131. Loprinzi CL, Barton DL, Sloan JA, et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause. 2008;15:655-660.
132. Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther. 2007;29:230-241. (Pubitemid 46661858)
133. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113-121. (Pubitemid 47555336)